These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37003278)

  • 1. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
    Srivastava A; Rangarajan S; Kavakli K; Klamroth R; Kenet G; Khoo L; You CW; Xu W; Malan N; Frenzel L; Bagot CN; Stasyshyn O; Chang CY; Poloskey S; Qiu Z; Andersson S; Mei B; Pipe SW
    Lancet Haematol; 2023 May; 10(5):e322-e332. PubMed ID: 37003278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
    Young G; Srivastava A; Kavakli K; Ross C; Sathar J; You CW; Tran H; Sun J; Wu R; Poloskey S; Qiu Z; Kichou S; Andersson S; Mei B; Rangarajan S
    Lancet; 2023 Apr; 401(10386):1427-1437. PubMed ID: 37003287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial.
    Kenet G; Nolan B; Zulfikar B; Antmen B; Kampmann P; Matsushita T; You CW; Vilchevska K; Bagot CN; Sharif A; Peyvandi F; Young G; Negrier C; Chi J; Kittner B; Sussebach C; Shammas F; Mei B; Andersson S; Kavakli K
    Blood; 2024 May; 143(22):2256-2269. PubMed ID: 38452197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
    Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
    Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
    Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
    Pasi KJ; Lissitchkov T; Mamonov V; Mant T; Timofeeva M; Bagot C; Chowdary P; Georgiev P; Gercheva-Kyuchukova L; Madigan K; Van Nguyen H; Yu Q; Mei B; Benson CC; Ragni MV
    J Thromb Haemost; 2021 Jun; 19(6):1436-1446. PubMed ID: 33587824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies.
    Mancuso ME; Croteau SE; Klamroth R
    Haemophilia; 2024 Apr; 30 Suppl 3():39-44. PubMed ID: 38481077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
    Iorio A; Königs C; Reding MT; Rotellini D; Skinner MW; Mancuso ME; Berntorp E
    Haemophilia; 2023 Jan; 29(1):33-44. PubMed ID: 36224704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.